Challenger Limited

FY26 normalized NPAT was $468 million, up 3%, and normalized EPS was $0.681, up 3%. Normalized ROE was 11.6%, above target for a second straight year. Statutory NPAT was $506 million, up 163%, helped by positive asset experience and unwind of the non-economic AASB 17 mismatch. Group net income was $995 million, total expenses were $319 million, and the cost-to-income ratio improved to 32.1%. Life sales rose 12% to $9.6 billion; long-dated 3-year-plus sales were $3.2 billion, and offshore reinsurance sales reached $1.2 billion. Investment assets grew 4% to $26.6 billion, and third-party assets under management were $4.1 billion, up 10%. The board declared a fully franked ordinary dividend of $0.315 per share, up 7%, plus a fully franked special dividend of $0.015 per share. PCA was 1.38x, or 1.5x pro forma under the new capital standards. For FY27, Challenger guided to core EPS of $0.45 to $0.49 per share, with the midpoint implying 6% growth from FY26 core EPS of $0.442. Medium-term targets are 8% to 10% operating EPS growth over 3 to 5 years, ROE of 12% to 14% after tax, dividend payout of 65% to 75% of core EPS, and PCA of 1.15x to 1.35x. Management also said the Fidante-Channel Capital merger is expected to complete in Q2 FY27, with an expected accounting pre-tax gain on sale of around $100 million in FY27, and Calix Re should add about $8 million post-tax of operating costs and timing drag in FY27.

Nick Hamilton framed FY26 as a turning point for Challenger’s retirement-income strategy, saying the business now has more resilience, more capital flexibility, and more ways to grow. He emphasized the structural shift from accumulation to retirement income, the importance of closing the advice gap, and the company’s role in lifetime income solutions. He was upbeat but disciplined, repeatedly stressing that growth will be driven without chasing yield and that the new capital standards change Challenger’s economics and capacity.

Alexandra Bell highlighted that the financial result was driven by both earnings growth and cost discipline. She cited normalized NPAT of $468 million, normalized EPS of $0.681, statutory NPAT of $506 million, and normalized ROE of 11.6%, while noting total expenses were held to $319 million and the cost-to-income ratio improved to 32.1%. She also pointed to PCA of 1.38x, pro forma 1.5x, the $0.315 ordinary dividend plus $0.015 special dividend, the $450 million buyback program, and the move to a target PCA range of 1.15x to 1.35x. On capital and future earnings, she said the new standards make the balance sheet more resilient, support growth without fresh equity, and allow retained earnings and buybacks to be used more flexibly.

Analysts focused on how Challenger’s new 8% to 10% operating EPS target was built, whether it assumes lower yield, buybacks, and how much growth comes from asset remixing versus underlying earnings. Management said the base year is FY26 and that the target reflects growth in core earnings, ROE expansion, and some continuation of buybacks, while also noting they are not assuming spread widening. Questions also probed the jump in FY27 maturity rates, the treatment of non-core investment returns, the impact of transition costs, and the tax rate for Calix Re; management said the higher maturity rate mainly reflects prior short-term institutional business rolling off, transition costs should mostly disappear by end-FY27, and the group effective tax rate should be just above 30% near term with Calix Re taxed in the U.S. at 21%.